SecBot SecBot
SECBOTREPLAY Home › Report › LAB

LAB · Standard BioTools (LAB) announced a definitive all-stock merger with…

Standard BioTools Inc. · PRESS-RELEASE filed Jun 8, 2026 at 07:30 ET

At the news

MIXEDIMPACT 7/10

PRESS-RELEASE filed Jun 8, 2026 at 07:30 ET

Standard BioTools (LAB) announced a definitive all-stock merger with Treeline Biosciences, a clinical-stage oncology biotech. LAB shareholders will own ~16% of the combined company (Treeline Biosciences, ticker TRLN), valued at net cash delivered at closing plus $10M (~$460M). The combined entity will have >$900M cash, funding operations into 2029, and Treeline's pipeline includes three Phase 1 programs with data readouts starting 2027. LAB's legacy Mass Cytometry and Microfluidics businesses will be divested. This is a transformative reverse-merger that effectively converts LAB into a development-stage biotech, with LAB shareholders receiving a minority stake and a CVR tied to legacy asset proceeds.

  • All-stock merger: LAB shareholders to own ~16% of combined company; Treeline shareholders ~84%.
  • Combined company to be named Treeline Biosciences, trading under ticker TRLN.
  • Transaction values LAB at net cash delivered at closing plus $10M, estimated at ~$460M.
  • Pro-forma cash >$900M at closing, providing runway into 2029.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access